← Theravance Biopharma, Inc. (TBPH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Theravance Biopharma, Inc. (TBPH)
Pharmaceutical Preparations · market cap $885M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
9
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Theravance Biopharma (TBPH) is a small-cap pharma with 97 employees and a ~$873M market cap, built around ampreloxetine, a Phase 3 asset targeting Symptomatic Neurogenic Orthostatic Hypotension (sNOH). The company carries $288M in cash and no net debt, giving it a meaningful financial cushion, while a diversified but early-stage pipeline spans gastroparesis, asthma, skin infections, and COPD. The next formal event is an August 11, 2026 earnings release.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TD-9855 | Phase 2 | Neurogenic Orthostatic Hypotension |
| TD-1792 | Phase 2 | Staphylococcal Skin Infection |
| Velusetrag | Phase 2 | Gastroparesis |
| TD-0903 | Phase 2 | Acute Lung Injury (ALI) Associated With COVID-19 |
| TD-8236 | Phase 2 | Asthma |
| ampreloxetine | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension |
| TD-9855 Group 1 | Phase 2 | Fibromyalgia |
| velusetrag dose 1 | Phase 2 | Gastroparesis |
| 400 microgrammes GSK961081 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
Price & technical context
3-month
-3.4%
6-month
+12.1%
12-month
+21.2%
52-wk range
$13.57–$20.74
vs 50-day MA
+0.4%
vs 200-day MA
-0.8%
Realized vol
45.9%
Max drawdown
-34.6%
Daily closes through 2026-09-25. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TBPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.